candesartan has been researched along with Arrhythmias, Cardiac in 6 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Arrhythmias, Cardiac: Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of low-dose carvedilol combined with candesartan in the prevention of acute and chronic cardiotoxicity of anthracycline drugs in adjuvant chemotherapy of breast cancer." | 9.17 | [Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer]. ( Han, YL; Liang, XF; Liu, L; Liu, YY; Liu, ZZ; Xie, XD; Zheng, ZD, 2013) |
| "To investigate the effect of low-dose carvedilol combined with candesartan in the prevention of acute and chronic cardiotoxicity of anthracycline drugs in adjuvant chemotherapy of breast cancer." | 5.17 | [Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer]. ( Han, YL; Liang, XF; Liu, L; Liu, YY; Liu, ZZ; Xie, XD; Zheng, ZD, 2013) |
| "Candesartan reduced CTGF expression and attenuated the fibrosis in diabetic rat atria." | 3.77 | Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling. ( Aizawa, T; Fu, LT; Kaneko, S; Kato, T; Sagara, K; Sekiguchi, A; Takamura, M; Tsuneda, T; Yamashita, T, 2011) |
| " We examined whether candesartan, an AT1 receptor blocker, has antiarrhythmic effects on mouse model of left ventricular hypertrophy created by transverse aorta constriction (TAC)." | 3.73 | Blockade of angiotensin II type 1 receptor improves the arrhythmia morbidity in mice with left ventricular hypertrophy. ( Horie, M; Kobori, A; Kuwahara, K; Makiyama, T; Yasuno, S; Zankov, DP; Zhang, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Muhailan, M | 1 |
| Al-Shbool, G | 1 |
| Higa, A | 1 |
| Hoshi, H | 1 |
| Yanagisawa, Y | 1 |
| Ito, E | 1 |
| Morisawa, G | 1 |
| Imai, JI | 1 |
| Watanabe, S | 1 |
| Takagi, M | 1 |
| Liu, L | 1 |
| Liu, ZZ | 1 |
| Liu, YY | 1 |
| Zheng, ZD | 1 |
| Liang, XF | 1 |
| Han, YL | 1 |
| Xie, XD | 1 |
| Kato, T | 1 |
| Yamashita, T | 1 |
| Sekiguchi, A | 1 |
| Tsuneda, T | 1 |
| Sagara, K | 1 |
| Takamura, M | 1 |
| Kaneko, S | 1 |
| Aizawa, T | 1 |
| Fu, LT | 1 |
| Zhang, C | 1 |
| Yasuno, S | 1 |
| Kuwahara, K | 1 |
| Zankov, DP | 1 |
| Kobori, A | 1 |
| Makiyama, T | 1 |
| Horie, M | 1 |
| Harada, K | 1 |
| Komuro, I | 1 |
| Hayashi, D | 1 |
| Sugaya, T | 1 |
| Murakami, K | 1 |
| Yazaki, Y | 1 |
1 trial available for candesartan and Arrhythmias, Cardiac
| Article | Year |
|---|---|
[Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antineoplastic Co | 2013 |
5 other studies available for candesartan and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Pseudo-Wellens' Syndrome Temporally Associated With Immune Check Point Inhibitors Use.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antineoplast | 2020 |
Evaluation system for arrhythmogenic potential of drugs using human-induced pluripotent stem cell-derived cardiomyocytes and gene expression analysis.
Topics: Amlodipine; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Compounds; Bisoprolol; Cardiotoxicity; Ce | 2017 |
Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Com | 2011 |
Blockade of angiotensin II type 1 receptor improves the arrhythmia morbidity in mice with left ventricular hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Com | 2006 |
Angiotensin II type 1a receptor is involved in the occurrence of reperfusion arrhythmias.
Topics: Angiotensin Receptor Antagonists; Animals; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Compounds; | 1998 |